FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.
Associations included higher prevalence of focal to bilateral tonic-clonic seizures in drug-resistant epilepsy ...
The leading causes of death in the US remained similar in 2024 as in 2023, according to the September 22 National Vital Statistics Reports, a publication from t ...
Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.
Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results